Taxus Liberté launched in Japan
This article was originally published in Clinica
Executive Summary
Boston Scientific has launched its Taxus Liberté paclitaxel-eluting stent in Japan. The product was approved on January 28 by the Ministry of Health, Labor and Welfare, and reimbursement was granted yesterday by the National Health Insurance System. Around 1,300 medical centres perform cardiac catheterisation in Japan, with an estimated at 200,000 coronary stents implanted annually.